Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

Aclaris Therapeutics Price Performance

NASDAQ:ACRS opened at $3.17 on Thursday. Aclaris Therapeutics has a 1-year low of $1.05 and a 1-year high of $4.89. The company has a 50-day moving average of $3.24 and a 200 day moving average of $2.52. The firm has a market cap of $343.47 million, a PE ratio of -2.30 and a beta of 0.86.

Analyst Ratings Changes

ACRS has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. Craig Hallum assumed coverage on Aclaris Therapeutics in a research report on Friday, January 30th. They set a “buy” rating and a $10.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a research report on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.80.

Institutional Investors Weigh In On Aclaris Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. increased its holdings in shares of Aclaris Therapeutics by 2.2% during the third quarter. Raymond James Financial Inc. now owns 283,476 shares of the biotechnology company’s stock valued at $539,000 after acquiring an additional 6,217 shares in the last quarter. Rhumbline Advisers grew its position in Aclaris Therapeutics by 7.4% during the 3rd quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 6,271 shares during the last quarter. Intech Investment Management LLC increased its stake in Aclaris Therapeutics by 19.8% during the 4th quarter. Intech Investment Management LLC now owns 46,646 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 7,702 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Aclaris Therapeutics by 59.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 9,894 shares in the last quarter. Finally, CIBC Asset Management Inc purchased a new position in shares of Aclaris Therapeutics in the fourth quarter worth $52,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.